NCT04812847 (InfGNMDR-Neo) is a clinical trial of Identification of MDR characteristics in Infant Newborn Disease, sponsored by Instituto Tecnologico y de Estudios Superiores de Monterey.

Who is sponsoring NCT04812847?

NCT04812847 is sponsored by Instituto Tecnologico y de Estudios Superiores de Monterey.

What drugs are being tested in NCT04812847?

Interventions in NCT04812847: Identification of MDR characteristics.

What condition does NCT04812847 study?

NCT04812847 studies Infant Newborn Disease.

Is NCT04812847 still recruiting?

NCT04812847 is currently completed. Last updated 1 March 2023.

Last reviewed 2023-03-01 · How we verify

NCT04812847: InfGNMDR-Neo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multidrug Resistant Gram-negative Pathogen Infections in High Risk Neonates in the Northeast of Mexico

Completed Last updated 1 March 2023

What this trial tests

trial testing Identification of MDR characteristics in Infant Newborn Disease in 597 participants. Completed in 31 December 2022.

Timeline

1 June 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Instituto Tecnologico y de Estudios Superiores de Monterey
Status	Completed
Study type	OBSERVATIONAL
Enrollment	597
Start date	1 June 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Mexico

Drugs / interventions tested

Identification of MDR characteristics

Conditions studied

Infant Newborn Disease — all drugs for Infant Newborn Disease →

Sponsor

Instituto Tecnologico y de Estudios Superiores de Monterey — full company profile →

Who can join

Adults 1 Day to 180 Days, any sex, with Infant Newborn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this project is to establish a prospective cohort to measure the Gram-negative infection burden in neonates under special care in a regional referral hospital, and to characterize all microorganisms isolates from these subjects at the phenotype and genotype level, specifically in relation to the expression of multi-drug resistance (MDR) associated genes (Molecular characterization of Gram-negative MDR isolates).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Genome sequences of 70 multidrug-resistant Gram-negative isolates in high-risk neonates in the Northeast of Mexico.
Rodriguez-Orduña L, Lara-Diaz VJ, Alcorta-Garcia MR, Lopez-Villaseñor CN, et al · · 2024 · cited 2× · PMID 39225481 · DOI 10.1128/mra.00274-24

Verify or expand the search:

Other Instituto Tecnologico y de Estudios Superiores de Monterey trials

Trials by the same sponsor.

NCT04983667 — Zinc-AA Supplementation During Pregnancy & Lactation to Assess Effects on ASD Prevalence in Offspring · NA · terminated
NCT03221153 — Patient Safety Skills for Medical Students · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04812847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Tecnologico y de Estudios Superiores de Monterey
Last refreshed: 1 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04812847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing